Expertise

Katya Svoboda

Partner

Expertise:

Commercialization, Compliance, Consulting (Strategy Management & Regulatory), Market Access, Pharmacovigilance, Pricing, Reimbursement & Market Access

Katya comes to EVERSANA Management Consulting from ICON, where she was Senior Principal/Interim Divisional Principal, Global Pricing and Market Access. In this role, Katya worked across teams on client engagements, internal initiatives, business development, and thought leadership, with responsibility for operations, finance, and people management.

Prior to ICON, Katya was a Senior Principal at ApotheCom, where she managed and executed consulting projects and communications initiatives while building the market access practice. Before ApotheCom, Katya was a Director at Navigant, where her projects included market access and commercialization consulting. Katya also co-founded Percipient LLC, a management consulting organization focused on pricing and market access strategy consulting, where she managed much of the company’s business and operational and HR activities.

Katya has a long history in consulting, including stints as Senior Practice Executive, Pricing and Market Access, at Campbell Alliance, Senior Director, Vice President & Managing Director, at inVentiv Advance Insights, Director at Strategyx, Consultant at Skila Consulting, Senior Consultant, Manager, at Arthur Andersen, and Senior Consultant at Deloitte & Touche.

Katya holds an MBA from Yale School of Management and a master’s degree in public health from Yale School of Medicine, Department of Epidemiology and Public Health. She earned her bachelor’s degree in economics and psychology from Boston University.

Articles by Katya Svoboda

Webinar Recording | From MFPs to MFN: Navigating the New Rules of Drug Pricing in 2026

In this recent webinar, experts John Neal, Katya Svoboda, and David Byram examine the major policy shifts transforming the U.S. drug pricing landscape—including the accelerating impact of MFN models, evolving MFPs, PBM transparency reforms, and the growth of direct-to-patient models. The discussion highlights how these policies intersect, the risks and opportunities they create for manufacturers, […]

Interested in scheduling a meeting or speaking event?

Contact Us